# psoriasis - grok-4.6

- Benchmark system: raw
- Repeat: 3
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 4061
- Completion tokens: 3071
- Reasoning tokens: 
- Total tokens: 7132
- API requests reported: 
- Elapsed seconds: 40.782
- Final benchmark system: raw; file rank 3/5; original repeat 3; model vendor: xAI

---
**1. Overall biological interpretation**

The transcriptomic profile from psoriatic lesional skin versus control skin is dominated by a coherent keratinocyte-centric signature: massive upregulation of genes that drive terminal differentiation, epidermal hyperplasia, and innate immune activation. The top-scoring genes (IL36A, DEFB4A, DEFB4B, S100A7A, SERPINB4) are all >10-fold elevated, indicating that the lesional epidermis is in a chronically activated, inflamed state with disrupted barrier function. This produces a self-reinforcing loop in which keratinocyte-derived alarmins and antimicrobial peptides recruit and activate neutrophils and T cells, further amplifying inflammation. The net result is the clinical picture of thick, scaly plaques. Minor downregulation of certain growth-factor and metabolic genes (BTC, CYP2W1) is consistent with altered wound-healing dynamics but is secondary to the dominant inflammatory/hyperproliferative program.

**2. Core biological programs**

**Program 1: Epidermal hyperproliferation and terminal differentiation**  
Direction: Strongly upregulated in lesional skin.  
Major genes: KRT6A, SPRR2A/B/D/E/F/G, SPRR3, DEFB4A/B, LCE3A/D.  
Pathway: Hallmark “KRAS signaling” + GO “keratinocyte differentiation” + Reactome “Epidermal differentiation”.  
Collective evidence: SPRR proteins replace filaggrin in the cornified envelope, KRT6A marks hyperproliferation, DEFB4A/B contribute to both barrier and alarmins. Together they produce the thickened, orthokeratotic stratum corneum of psoriasis.  
Evidence strength: High (multiple independent genes, concordant direction). Limitations: Does not distinguish primary keratinocyte change from secondary response to infiltrating immune cells.

**Program 2: Innate immune activation and alarmin/cytokine signaling**  
Direction: Strongly upregulated.  
Major genes: IL36A, IL36G, IL36RN, IL26, S100A7/A8/A12, SERPINB3/B4.  
Pathway: Reactome “Interleukin-36 signaling” + GO “positive regulation of cytokine production” + Hallmark “TNF-α signaling via NF-κB”.  
Collective evidence: IL-36 ligands are potent keratinocyte activators; S100A8/A9/MRP8/14 form calprotectin that amplifies neutrophilic inflammation; serpins inhibit proteases and modulate TGF-β/IL-17 pathways. The program is self-amplifying.  
Evidence strength: Very high (top-ranked genes, multiple members of the same families). Limitations: Overlap with secondary immune-cell infiltration; does not prove causality.

**Program 3: Skin-barrier breakdown**  
Direction: Strongly upregulated (disruption).  
Major genes: GJB2, GJB6, SPRR2 family, LCE3A, SERPINB4.  
Pathway: GO “epidermal barrier” + Reactome “Gap junction trafficking and vesicle-mediated transport”.  
Collective evidence: Connexins (GJB2/6) impair intercellular communication; SPRR and LCE proteins fail to form a functional lipid envelope; SERPINB4 inhibits kallikreins needed for desquamation. The barrier is both structurally defective and chemically altered.  
Evidence strength: High (multiple genes, concordant direction, consistent with clinical scale). Limitations: Cannot separate primary filaggrin-pathway defects from secondary inflammation.

**Program 4: Antimicrobial peptide and neutrophil activation**  
Direction: Strongly upregulated.  
Major genes: DEFB4A/B, S100A7/A8/A12, SERPINB4.  
Pathway: GO “defense response to bacterium” + Hallmark “Inflammatory response”.  
Collective evidence: DEFB4A/B are canonical AMPs; S100 proteins chelate metals and amplify TLR signaling; serpins modulate protease activity that controls AMP release. The program is both host-defense and tissue-damaging.  
Evidence strength: High (top-ranked genes, direct functional literature). Limitations: Overlap with Program 2; cannot distinguish direct keratinocyte AMP production from neutrophil-derived calprotectin.

**3. Key genes and interaction modules**

- **IL36A**: Highest log2FC (11.37); central to Program 2; drives IL-36R signaling and keratinocyte IL-17/IL-23 amplification (regulatory interaction via NF-κB).  
- **DEFB4A/B**: log2FC 11.18/11.03; core of Program 4 and Program 1; direct antimicrobial peptides that also chemoattract neutrophils (co-expression with S100A genes).  
- **S100A7A**: log2FC 9.83; Program 2 & 4; forms heterodimers with S100A8/A9 (direct protein interaction).  
- **SERPINB4**: log2FC 9.12; Programs 2 & 3; inhibits kallikreins and modulates TGF-β (pathway co-membership with IL-36).  
- **SPRR2A**: log2FC 7.31; Programs 1 & 3; component of cornified envelope (co-expression with KRT6A).  
- **GJB2/GJB6**: log2FC 4.42/3.02; Program 3; form gap junctions; impaired function leads to barrier defects (direct physical interaction).  
- **S100A12**: log2FC 8.33; Programs 2 & 4; neutrophil chemoattractant and TLR4 ligand (co-expression with CXCR2).  
- **BTC**: log2FC –4.30; downregulated; EGFR ligand involved in wound healing (regulatory interaction with EGFR signaling).  
- **CXCL13**: log2FC 5.89; Programs 2 & 4; T-cell and B-cell chemoattractant (co-expression with CXCR5 in lymphoid aggregates).  
- **IL26**: log2FC 4.36; Programs 2 & 4; Th17-derived cytokine that signals via IL-20R (regulatory interaction with IL-36).

**4. Validation priorities**

1. **Mechanistic hypothesis**: Test whether IL36A-driven signaling is required for SPRR/KRT6 induction in human keratinocytes. Next step: CRISPR knockout of IL36R in primary keratinocytes followed by RNA-seq after stimulation. Classification: Supported hypothesis.  
2. **Biomarker**: Validate top 5 genes (IL36A, DEFB4A, S100A7A, SERPINB4, SPRR2A) by qRT-PCR on laser-microdissected lesional epidermis and correlate with PASI score or histopathology. Classification: Biomarker.  
3. **Therapeutic target**: Assess whether neutralizing IL-36 or calprotectin reduces keratinocyte hyperproliferation in organotypic skin models. Next step: anti-IL-36R monoclonal antibody in a humanized mouse xenograft psoriasis model. Classification: Exploratory hypothesis (drug-target evidence exists but not yet disease-specific).  
4. **Interaction / network hypothesis**: Confirm physical interaction between S100A7/A8 and DEFB4 peptides in the epidermal microenvironment using proximity ligation assays. Classification: Interaction/network hypothesis.  
5. **Confounding or composition check**: Assess whether neutrophil infiltration (measured by CD66b IHC) or keratinocyte purity (measured by KRT14/KRT1 ratio) confounds the observed expression signatures. Next step: flow-sorted keratinocyte RNA-seq. Classification: Confounding or composition check.

**5. Evidence grounding**

All programs are grounded in:  
- Direct evidence from the input dataset (expression direction and magnitude).  
- Pathway/ontology evidence (GO/Reactome/Hallmark annotations of the gene sets).  
- Disease-association evidence (multiple prior psoriasis transcriptomic studies).  
- Protein-interaction/regulatory evidence (literature for S100–DEFB4, IL-36–IL-17R, SPRR–filaggrin).  
- Expression/tissue-specific evidence (keratinocyte-enriched genes).  
- Genetic/clinical evidence (filaggrin loss-of-function mutations cause barrier defects in psoriasis).  
No conflicting evidence; all sources converge on the same coherent picture. No “insufficient evidence” categories.

**6. Limitations and alternative explanations**

- Lesional skin is a cellular mixture; infiltrating neutrophils, T cells, and macrophages contribute calprotectin, cytokines, and proteases that may secondarily upregulate keratinocyte genes (composition confound).  
- Disease severity and duration vary; acute vs. chronic lesions may show different signatures (small-subgroup or stage effects).  
- Treatment exposure (topical steroids, phototherapy, biologics) can modulate gene expression in real-world cohorts.  
- Batch/platform effects possible in public datasets, though FDRs are uniformly low.  
- Association vs. causation: the data cannot distinguish whether keratinocyte activation is primary or a secondary response to an unknown initiating trigger (e.g., microbiome, autoantigen).  

All interpretations remain strictly correlative with the provided expression matrix.
